No major differences ... and discounted brand-name drugs. The report provides estimated price thresholds that CMS should ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

Chloe Thornton, GlobalData's company analyst, also recently observed that GSK has major problems with a lack ... The biggest vaccine brand it has acquired in the deal is Bexsero, a new vaccine ...

"JP Morgan 2025: GSK acquires IDRx in $1.15bn deal " was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in ...

After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the treatment landscape for multiple myeloma. The US Food and Drug ...

having the business as part of GSK gave it more stability, letting the pharma side of the business take more risks. Read more: Two huge drugmakers are spinning off iconic brands like Advil ...

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

GSK has drawn on a vast bank of images and conversations from ... In compiling a recent case for long-term, sustained investment in brand, we were able to support key marketing principles with ...

The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).1,2 Tony Wood, Chief Scientific Officer, ...